Bhuiyan Mejbah Uddin, Snelling Thomas L, West Rachel, Lang Jurissa, Rahman Tasmina, Borland Meredith L, Thornton Ruth, Kirkham Lea-Ann, Sikazwe Chisha, Martin Andrew C, Richmond Peter C, Smith David W, Jaffe Adam, Blyth Christopher C
Division of Paediatrics, Faculty of Health and Medical Sciences, School of Medicine, The University of Western Australia, Perth, Western Australia, Australia.
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia.
BMJ Open. 2018 Mar 16;8(3):e020646. doi: 10.1136/bmjopen-2017-020646.
Pneumonia is the leading cause of childhood morbidity and mortality globally. Introduction of the conjugate B and multivalent pneumococcal vaccines in developed countries including Australia has significantly reduced the overall burden of bacterial pneumonia. With the availability of molecular diagnostics, viruses are frequently detected in children with pneumonia either as primary pathogens or predispose to secondary bacterial infection. Many respiratory pathogens that are known to cause pneumonia are also identified in asymptomatic children, so the true contribution of these pathogens to childhood community-acquired pneumonia (CAP) remains unclear. Since the introduction of pneumococcal vaccines, very few comprehensive studies from developed countries have attempted to determine the bacterial and viral aetiology of pneumonia. We aim to determine the contribution of bacteria and viruses to childhood CAP to inform further development of effective diagnosis, treatment and preventive strategies.
We are conducting a prospective case-control study (PneumoWA) where cases are children with radiologically confirmed pneumonia admitted to Princess Margaret Hospital for Children (PMH) and controls are healthy children identified from PMH outpatient clinics and from local community immunisation clinics. The case-control ratio is 1:1 with 250 children to be recruited in each arm. Nasopharyngeal swabs are collected from both cases and controls to detect the presence of viruses and bacteria by PCR; pathogen load will be assessed by quantitative PCR. The prevalence of pathogens detected in cases and controls will be compared, the OR of detection and population attributable fraction to CAP for each pathogen will be determined; relationships between pathogen load and disease status and severity will be explored.
This study has been approved by the human research ethics committees of PMH, Perth, Australia (PMH HREC REF 2014117EP). Findings will be disseminated at research conferences and in peer-reviewed journals.
肺炎是全球儿童发病和死亡的主要原因。在包括澳大利亚在内的发达国家引入结合型B族和多价肺炎球菌疫苗后,细菌性肺炎的总体负担显著降低。随着分子诊断技术的出现,在肺炎患儿中经常检测到病毒,这些病毒要么是主要病原体,要么易引发继发性细菌感染。许多已知可引起肺炎的呼吸道病原体在无症状儿童中也能被检测到,因此这些病原体对儿童社区获得性肺炎(CAP)的真正影响仍不明确。自肺炎球菌疫苗引入以来,发达国家很少有全面的研究试图确定肺炎的细菌和病毒病因。我们旨在确定细菌和病毒对儿童CAP的影响,为进一步制定有效的诊断、治疗和预防策略提供依据。
我们正在进行一项前瞻性病例对照研究(PneumoWA),病例为入住玛格丽特公主儿童医院(PMH)且经放射学确诊为肺炎的儿童,对照为从PMH门诊和当地社区免疫诊所确定的健康儿童。病例对照比为1:1,每组招募250名儿童。从病例和对照中采集鼻咽拭子,通过聚合酶链反应(PCR)检测病毒和细菌的存在;病原体载量将通过定量PCR进行评估。比较病例和对照中检测到的病原体的患病率,确定每种病原体的检测比值比(OR)和对CAP的人群归因分数;探讨病原体载量与疾病状态和严重程度之间的关系。
本研究已获得澳大利亚珀斯PMH人类研究伦理委员会(PMH HREC REF 2014117EP)的批准。研究结果将在研究会议和同行评审期刊上发表。